The death of the IPO has been greatly exaggerated. Here's why.

The current narrative suggests private equity is overtaking high-quality small-cap companies, sidelining them from public markets. However, a deeper look reveals that this perception may be overblown.

While private capital has indeed focused heavily on the tech sector, other industries like biotechnology are experiencing robust public market participation and IPO activity. The IPO landscape remains healthy and resilient, with increasing numbers of offerings in recent years indicating sustained interest from small-cap firms seeking growth through public funding.

This trend highlights that despite the influence of private equity, innovation across sectors continues to drive expansion in public markets, challenging the notion of a declining IPO environment.